Table 3 Factors that may affect the 6-month CRR.
Clinical features | Patients achieved CR (n = 16) | Patients not achieved CR (n = 66) | P value |
|---|---|---|---|
Median age (range), yrs | 64.5 (60–82) | 66 (60–84) | 0.916 |
Male/female (n) | 9/7 | 29/37 | 0.376 |
The median duration from diagnosis to treatment (days, range) | 0.7 (0.3–11.8) | 1.3 (0.2–35.8) | 0.461 |
Severity classification, no. (%) | 0.662 | ||
SAA | 14 (87.5%) | 52 (78.8%) | |
VSAA | 2 (12.5%) | 14 (21.2%) | |
HGB (g/L) | 54 (33–77) | 60 (25–82) | 0.163 |
PLT (×1012/L) | 7 (1–26) | 8(1–43) | 0.389 |
WBC (×109/L) | 1.79 (0.74–4.04) | 2.04 (0.42–3.77) | 0.680 |
ANC (×109/L) | 0.56 (0.15–0.94) | 0.54 (0.04–1.49) | 0.935 |
Fer (μg/L) | 1022.25 (165–2818) | 903.5 (11–6409) | 0.888 |
PNH clone-positive, no. (%) | 3 (18.8%) | 14 (21.2%) | 1.000 |
Chromosomal karyotype abnormality, no. (%) | 2(12.5%) | 9 (13.6%) | 1.000 |
Myeloid gene mutation, no. (%) | 6 (37.5%) | 16 (24.2%) | 0.448 |
Treatment, no. (%) | 1.000 | ||
ATG+CsA+AVA | 8 (50%) | 33 (50%) | |
CsA+AVA | 8 (50%) | 33 (50%) | |
3-month response, no. (%) | |||
ORR | 15 (93.8%) | 33 (50%) | 0.001 |
CRR | 3 (18.8%) | 1 (1.5%) | 0.022 |
